Immunologic dysfunction in cancer

Hematology/Oncology Clinics of North America

Volumn 10, Issue 4, 1996, Pages 927-952

  Kavanaugh, D Y ^a   Carbone, D P ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HEAT SHOCK PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTATION; CANCER; CANCER PREVENTION; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; HOST RESISTANCE; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; PRIORITY JOURNAL; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE;

EID: 0029999851     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70376-2     Document Type: Article

References (233)

1. A.C. Aisenberg Lymphocytopenia in Hodgkin's disease Blood 25 1965 1037
2. A.C. Aisenberg Studies on delayed hypersensitivity in Hodgkin's disease J Clin Invest 41 1962 1964
3. A.C. Aisenberg S. Leskowitz Antibody formation in Hodgkin's disease N Engl J Med 268 1963 1269
4. J.P. Allison CD28-B7 interactions in T-cell activation Curr Opin Immunol 6 1994 414
5. T.C. Anderson S.E. Jones B.J. Soehnlen Immunocompetence and malignant lymphoma: Immtmologic status before therapy Cancer 48 1981 2702
6. H.M. Anthony J.A. Kirk K.E. Madsen E and EAC rosetting lymphocytes in patients with carcinoma of bronchus. I. Some parameters of the test and its prognostic significance Clin Exp Immunol 20 1975 29
7. M. Azuma M. Cayabyab J.H. Phillips L.L. Lanier Requirements for CD28-dependent T-cell mediated cytotoxicity J Immunol 150 1993 2091
8. C.M. Balch P.A. Dougherty A.B. Tilden Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients Ann Surg 196 1982 645
9. R.W. Baldwin M.J. Embleton M.R. Price A. Robins Immunity in the tumor-bearing host and its modification by serum factors Cancer 34 1974 1452
10. S. Baskar S. Ostrand-Rosenberg N. Nabavi Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules Proc Natl Acad Sci USA 90 1993 5687
11. J.C. Becker T. Brabletz C. Czerny Tumor escape mechanisms from immunosur-veillance: Induction of unresponsiveness in a specific MHC-restricted CD4 + human T cell clone by the autologous MHC class II + melanoma Int Immunol 5 1993 1501
12. J.C. Becker R. Dummer A.A. Hartmann Shedding of ICAM-1 from human melanoma cell lines induced by IFN-γ and tumor necrosis factorα J Immunol 147 1991 4398
13. J.C. Becker C. Termeer R.E. Schmidt E.-B. Brocker Soluble intercellular adhesion mole-cule-1 inhibits MHC-restricted specific T cell/tumor interaction J Immunol 1S1 1993 7224
14. A.H. Bill A. Morgan Evidence for immune reactions to neuroblastoma and future possibilities for investigations J Pediatr Surg 5 1970 111
15. A.M. Bobrove Z. Fuks S. Strober H.S. Kaplan Quantitation of T and B lymphocytes and cellular immune dysfunction in Hodgkin's disease Cancer 36 1975 169
16. S. Bodmer K. Strommer K. Frei Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β2 J Immunol 143 1989 3222
17. T. Boon Toward a genetic analysis of tumor rejection antigens Adv Cancer Res 58 1992 177
18. J.L. Bosworth S. Thaler N.A. Ghossein Delayed hypersensitivity and local control of patients treated by radiotherapy for head and neck cancer Am J Surg 132 1976 46
19. M.W. Boyer P.J. Orchard K.B. Gorden Dependency on intercellular adhesion molecule recognition and local interleukin-2 provision in generation of an in vivo CD8 + T-cell immune response to murine myeloid leukemia Blood 85 1995 2498
20. V. Brichord A. Van Pel T. Wolfel The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas J Exp Med 178 1993 489
21. + T cell infiltration J Immunol 149 1992 2954
22. S. Broder T.A. Waldmann The suppressor-cell network in cancer N Engl J Med 299 1978 1281
23. W.H. Brooks M.G. Netsky D.E. Normansell D.A. Horwitz Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor J Exp Med 136 1972 1631
24. R.S. Brown H.A. Haynes H.T. Foley Hodgkin's disease. Immunological, clinical and histological features of 50 untreated patients Ann Intern Med 67 1967 291
25. M. Buferne F. Luton F. Letourneur Role of CD3δ in surface expression of the TCR/CD3 complex and in activation for killing analyzed with CD3δ-negative cyto-toxic T lymphocyte variant J Immunol 148 1992 657
26. R.M. Bukowski S. Noguchi J.S. Hewlett S. Deodhar Lymphocyte subpopulations in Hodgkin's disease Am J Clin Pathol 65 1976 31
27. F.A. Campbell H.P. Redmond D. Bouchier-Hayes The role of tumor rejection antigens in host antitumor defense mechanisms Cancer 75 1995 2649
28. D.C. Case J.A. Hansen E. Corrales Comparison of multiple in vivo and in vitro parameters in untreated patients with Hodgkin's disease Cancer 38 1976 1807
29. W.J. Catalona P.B. Chretien Abnormalities of quantitative dinitrochlorobenzene sensiti-zation in cancer patients: Correlation with tumor stage and histology Cancer 31 1973 353
30. W.J. Catalona W.F. Sample P.B. Chretien Lymphocyte reactivity in cancer patients: Correlation with tumor histology and clinical stage Cancer 31 1973 65
31. R.C. Chakravorty H.P. Curutchet F.S. Coppolla The delayed hypersensitivity reaction in the cancer patient: Observations on sensitization by DNCB Surgery 73 1973 730
32. L. Chen S. Ashe W.A. Brady Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 Cell 71 1992 1093
33. L. Chen P.S. Linsley K.E. Hellstrom Costimulation of T cells for tumor immunity Immunol Today 14 1993 483
34. L. Chen P. McGowan S. Ashe Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity J Exp Med 179 1994 523
35. N.V. Cheung E. Walter W.H. Smith-Mensah Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro J Clin Invest 81 1988 1122
36. M. Chilosi G. Semenzato F. Vinante Increased levels of soluble interleukin-2 receptor in non-Hodgkin's lymphoma Am J Clin Pathol 92 1989 2186
37. I.F. Ciernik D.P. Carbone Tumor suppressor gene-derived peptide antigens Methods in Enzymology 8 1995 225
38. I.F. Ciernik B.H. Krayenbuhl Ciernik C.J. Cockerell Expression of transforming growth factor beta and transforming growth factor beta receptors on AIDS-associated Kaposi's sarcoma Clinical Cancer Research 1 1995 1119
39. N.R. Cooper Complement evasion strategies of microorganisms Immunol Today 12 1991 327
40. M.P. Corder R.C. Young R.S. Brown V.T. DeVita Pytohemagglutinin-induced lympho-cyte transformation: The relationship to prognosis of Hodgkin's disease Blood 39 1972 595
41. C. Cordon-Cardo Z. Fuks M. Drobnjak Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas Cancer Res 51 1991 6372
42. P.G. Coulie F. Lehmann B. Lethe A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma Proc Natl Acad Sci USA 92 1995 7976
43. F.V. Cromme J. Airey M.T. Heemels Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinoma J Exp Med 179 1994 335
44. F.V. Cromme P.F.J. van Bommel J.M.M. Walboomers Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumors Br J Cancer 69 1994 1176
45. C.M. D'Urso Z. Wang Y. Cao Loss of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression J Clin Invest 87 1991 284
46. B.I. Dalai P.A. Keown A.H. Greenberg Immunocytochemical localization of secreted transforming growth factor-β1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma Am J Pathol 143 1993 381
47. J. Dalmau F. Graus M.K. Rosenblum J.B. Posner Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients Medicine (Baltimore) 71 1992 59
48. M. De Sousa M. Yang E. Lopes-Corrales Ecotaxis: The principle and its application to the study of Hodgkin's disease Clin Exp Immunol 27 1977 143
49. A. Dellon C. Potvin P.B. Chretien Thymus-dependent lymphocyte levels in broncho-genic carcinoma: Correlations with histology, clinical stage and clinical course after surgical treatment Cancer 35 1975 687
50. A. Doyle W.J. Martin K. Funa Markedly decreased expression of class I histocom-patibility antigens, protein, and mRNA in human small-cell lung cancer J Exp Med 161 1985 1135
51. J. Ducos J. Migueres P. Colombies Lymphocyte response to P.H.A. in patients with lung cancer Lancet 1 1970 1111
52. E.C. Ebert A.I. Roberts D. Devereux H. Nagase Selective immune-suppressive action of a factor produced by colon cancer cells Cancer Res 50 1990 6158
53. F.R. Eilber D.L. Morton Immunologic abnormalities in head and neck cancer Am J Surg 128 1974 534
54. F.R. Eilber D.L. Morton Impaired immunologic reactivity and recurrence following cancer surgery Cancer 25 1970 362
55. J.R. Eltringham H.S. Kaplan Impaired delay-hypersensitivity responses in 154 patients with untreated Hodgkin's disease Natl Cancer Inst Monogr 36 1973 107
56. M. Estevez L. Sen A.E. Bachmann A. Pavlovsky Defective function of peripheral blood monocytes in patients with Hodgkin's disease and non-Hodgkin's lymphomas Cancer 46 1980 299
57. J.H. Finke A.H. Zea J. Stanley Loss of T-cell receptor d chain and p561ck in T-cells infiltrating human renal cell carcinoma Cancer Res 53 1993 5613
58. G.J. Freeman A.S. Freedman J.M. Segil B7, a new member of the Ig superfamily with unique expression on the activated and neoplastic B cells J Immunol 143 1989 2714
59. S. Fujimoto M.I. Greene A.H. Sehon Regulation of the immune response to tumor antigens. II. The nature of immunosuppressor cells in tumor-bearing hosts J Immunol 116 1976 800
60. K.J. Gajl-Peczalska C.D. Bloomfield H. Sosin J.H. Kersey B and T lymphocytes in Hodgkin's disease. Analysis at diagnosis and following therapy Clin Exp Immunol 23 1976 47
61. J. Garcia-Sanz H.R. MacDonald D.E. Jenne Cell specificity of granzyme gene expression J Immunol 145 1990 3111
62. O. Garraud A. Faucher E. Legrand Impairment of monocyte functions in advanced head and neck cancer Immunol Lett 18 1988 213
63. R.N. Germain MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation Cell 76 1994 287
64. J.S. Goodwin A.D. Bankhurst R.P. Messner Suppression of human T cell mitogenesis by prostaglandin J Exp Med 146 1977 1719
65. J.S. Goodwin R.P. Messner A.D. Bankhurst Prostaglandin-producing suppressor cells in Hodgkin's disease N Engl J Med 297 1977 963
66. S.M. Gorsch V.A. Memoli T.A. Stukel Immunohistochemical staining for transforming growth factor β associates with disease progression in human breast cancer Cancer Res 52 1992 6949
67. W.C. Greene W.J. Leonard J.M. Depper The human interleukin-2 receptor: Normal and abnormal expression in T cells and in leukemias induced by the human T-lymphotropic retroviruses Ann Intern Med 105 1986 560
68. C.D. Gregory R.J. Murray C.F. Edwards A.B. Rickinson Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance J Exp Med 167 1988 1811
69. R.L. Gross A. Latty E.A. Williams P.M. Newbernem Abnormal spontaneous rosette formation and rosette inhibition in lung carcinoma N Engl J Med 292 1975 439
70. H.-J. Gruss G. Dolken M.A. Brach Serum levels of circulating ICAM-1 are increased in Hodgkin's disease Leukemia 7 1993 1245
71. Y. Gunji S. Hori T. Aoe High frequency of cancer patients with abnormalassembly of the T cell receptor-CD3 complex in peripheral blood T lymphocytes Jpn J Cancer Res 85 1994 1189
72. T. Han H. Takita Immunologic impairment in bronchogenic carcinoma: A study of lymphocyte response to phytohemagglutinin Cancer 30 1972 616
73. T. Hara A. Kojima H. Fukuda Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies Br J Haematol 82 1992 368
74. F.A. Harding P. Allison CD28-B7 interactions allow the induction of CD8 + cytotoxic T lymphocytes in the absence of exogenous help J Exp Med 177 1993 1791
75. R. Harning E. Mainolfi J.-C. Bystryn Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma Cancer Res 51 1991 5003
76. I. Hart A. Saini Biology of tumor metastasis Lancet 339 1992 1453
77. K.E. Hellstrom I. Hellstrom Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens Adv Immunol 18 1974 209
78. E.M. Hersh J.J. Oppenheim Impaired in vitro lymphocyte transformation in Hodgkin's disease N Engl J Med 273 1965 1006
79. E.Y. Hilal H.J. Wanebo C.M. Pinsky Immunological evaluation and prognosis in patients with head and neck cancer Am J Surg 134 1977 469
80. C.G.J.M. Hilders I.M. Munoz Y. Nooyen G.J. Fleuren Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance Gynecol Oncol 57 1995 366
81. G. Holm H. Mellstedt M. Bjorkholm Lymphocyte abnormalities in untreated patients with Hodgkin's disease Cancer 37 1976 751
82. L.J. Humphrey M.A. Humphrey O. Singla F.J. Volenec Immunologic responsiveness of patients with cancer Ann Surg 193 1981 574
83. M.L. Iruela-Arispe E.H. Sage Endothelial cells exhibiting angiogenesis in vitro prolifer- ate in response to TGF-β1 J Cell Biochem 52 1993 414
84. M. Jaattela Overexpression of major heat shock protein hsp70 inhibits tumor necrosis factor-induced activation of phopholipase A2 J Immunol 151 1993 4286
85. M. Jaattela D. Wissing P.A. Bauer G.C. Li Major heat shock protein hsp70 protects tumor cells from tumor necrosis factor cytotoxocity EMBO J 11 1992 3507
86. P. Jachimczak U. Bogdahn J. Schneider The effect of transforming growth factor-B2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in glioma J Neurosurg 78 1993 944
87. T.R. Jerrells J.H. Daon G.L. Richardson Role of suppressor cells in expression of in vitro lymphoproliferative responses of lung cancer and breast cancer patients J Natl Cancer Inst 61 1978 1001
88. J.P. Johnson B.G. Stade B. Holzmann De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk for metastasis Proc Natl Acad Sci USA 86 1989 641
89. N. Jonjic S. Alberti S. Bernasconi Heterogenous susceptibility of human mela-noma clones to monocyte cytotoxicity: Role of ICAM-1 defined by antibody blocking and gene transfer Eur J Immunol 22 1992 2255
90. M.E. Kadin M.W. Cavaille-Coll R. Gertz Loss of receptors for transforming growth factor B in human T-cell malignancies Proc Natl Acad Sci USA 91 1994 6002
91. T. Kageshita Z. Wang L. Calorini Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens Cancer Res 53 1993 3349
92. L. Kaklamanis A. Townsend I.A. Doussis-Anagnostopoulou Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer Am J Pathol 145 1994 505
93. K. Karjalainen High sensitivity, low affinity--paradox of T-cell receptor recognition Curr Opin Immunol 6 1994 9
94. J. Kaur A.S.D. Speirs D. Catavsky D.A.G. Gaiton Increase of T lymphocytes in the spleen in Hodgkin's disease Lancet 2 1974 800
95. N.E. Kay J. Burton D. Wagner D.L. Nelson The malignant B cells from B-chroniclymphocytic leukemia patients release TAC-soluble interleukin-2 receptors Blood 72 1988 447
96. J.H. Kerhl A.B. Roberts L.M. Wakefield Transforming growth factor β is an important immunomodulatory protein for human B lymphocytes J Immunol 137 1986 3855
97. J.H. Kerhl L.M. Wakefield A. Roberts Production of transforming growth factor[3 by human T lymphocytes and its potential role in regulation of T cell growth J Exp Med 163 1986 1037
98. T. Kinoshita Biology of complement: The overture Immunol Today 12 1991 291
99. H. Kirchner Suppressor cells of immune reactivity in malignancy Eur J Cancer 14 1978 453
100. G. Klein H. Sjogren E. Klein K.E. Hellstrom Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host Cancer Res 20 1960 1561
101. T. Koneval E. Applebaum D. Popovic Demonstration of immunoglobulin in tumor and marginal tissues of squamous cell carcinomas of the head and neck J Natl Cancer Inst 59 1977 1089
102. K. Koretz S. Bruderlein C. Henne P. Moller Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenoma, and carcinomas Br J Cancer 66 1992 810
103. S.E. Kornguth Neuronal proteins and paraneoplastic syndromes N Engl J Med 321 1989 1607
104. S. Koyama Immunosuppressive effect of shedding intercellular adhesion molecule 1 antigen on cell-mediated cytotoxicity against tumor cells Jpn J Cancer Res 85 1994 131
105. S. Koyama T. Ebihara K. Fukao Expression of intercellular adhesion molecule 1 (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma Cancer Res Clin Oncol 118 1992 609
106. M.J. Krant G. Manskopf C.S. Brandrup M.A. Madoff Immunologic alterations in bron-chogenic cancer Cancer 21 1968 623
107. B.R. Ksander J.W. Streilein Failure of infiltrating precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites J Immunol 145 1990 2057
108. S. Kumar J.M. Vinci B.A. Pytel C. Baglioni Expression of messenger RNAs for complement inhibitors in human tissues and tumors Cancer Res 53 1993 348
109. M.C. Kuppner M.F. Hamou S. Bodmer The glioblastoma-derived T-cell suppres-sor factor/transforming growth factor beta 2 inhibits the generation of lymphokine-activated killer (LAK) cells Int J Cancer 42 1988 562
110. M. Kuraya E. Yefenof G. Klein E. Klein Expression of the complement regulatory proteins CD21, CD55, Cd59 on Burkitt lymphoma lines: Their role in sensitivity to human serum-mediated lysis Eur J Immunol 22 1992 1871
111. R. Lafreniere K. Borkenhagen L. Bryant MC-38 adenocarcinoma tumor infiltrating lymphocytes: Correlation of cytotoxicity with time of tumor harvest after tumor inoculation J Surg Oncol 43 1990 8
112. K.N. Lai S. Ho J.C.K. Leung S.Y. Tsao Soluble interleukin-2 receptors in patients with nasopharyngeal carcinoma Cancer 67 1991 2180
113. D. Lamb F. Pilney W.D. Kelly R. Good A comparative study of the incidence of anergy in patients with carcinoma, leukemia, Hodgkin's disease and other lymphomas J Immunol 89 1962 555
114. E.C. Lattime O. Stutman Tumor growth in vivo selects for resistance to tumor necrosis factor J Immunol 143 1989 4317
115. A.H. Laughter J.J. Twomey Suppression of lymphoproliferation by high concentrations of normal human mononuclear leukocytes J Immunol 119 1977 173
116. L. Leb J.A. Merritt Decreased monocyte function in patients with Hodgkin's disease Cancer 41 1978 1794
117. Lee CT, Ciernik IF, Wu S, et al: Increased immunogenicity of tumors bearing mutant p53 and P1A epitopes after transduction of B7-1 via recombinant adenovirus. Cancer Gene Therapy, in press
118. G. Lee L.R. Ellingsworth S. Gillis B transforming growth factors are potential regulators of B lymphopoiesis J Exp Med 166 1987 1290
119. Y.-T. Lee F.C. Sparks F.R. Eilber D.L. Morton Delayed cutaneous hypersensitivity and peripheral lymphocyte counts in patients with advanced cancer Cancer 35 1975 748
120. M. Lenardo A.K. Rustgi A.R. Schievella R. Bernards Suppression of MHC class I gene expression by N-myc through enhancer inactivation EMBO J 8 1989 3351
121. R. Levy H.S. Kaplan Impaired lymphocyte function in untreated Hodgkin's disease N Engl J Med 290 1974 181
122. A. Lichtenstein J. Zighelboim F. Dorey Comparison of immune derangements in patients with different malignancies Cancer 45 1980 2090
123. N.L. Lill M.J. Tevethia W.G. Hendrickson S.S. Tevethia Cytotoxic T lymphocytes (CTL) against a transforming gene product select for transformed cells with point mutations within sequences encoding CTL recognition epitopes J Exp Med 176 1992 449
124. P. Linsley J. Ledbetter The role of the CD28 receptor during T cell responses to antigen Annu Rev Immunol 11 1993 191
125. P. Lissoni S. Barni F. Rovelli The biological significance of soluble interleukin-2 receptors in solid tumors Eur J Cancer 26 1990 33
126. Y. Liu P. Linsley Costimulation of T cell growth Curr Opin Immunol 4 1992 265
127. Y.K. Liu M. Grimaldi C.L. Dannaher Myelopoietic abnormalities in patients with metastatic cancer Cancer 41 1978 1193
128. C.M. Loeffler M.J. Smyth D. Longo Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8 + T cells J Immu-nol 149 1992 949
129. M.A. Lopez-Nevot R. Esteban A. Ferron HLA class I gene expression on human primary tumours and autologous metastases: Demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas Br J Cancer 59 1989 221
130. R.D. Maca W.R. Panje Indomethacin sensitive suppressor cell activity in head and neck cancer patients pre- and postirradiation therapy Cancer 50 1982 483
131. D.L. Maccubbin K.F. Mace M.J. Ehrke Modification of host antitumor defense mechanisms in mice by progressively growing tumor Cancer Res 49 1989 4216
132. R.H. Maisel J.H. Ogura Abnormal dinitrochlorobenzene skin sensitization: A prognostic sign of survival in head and neck squamous cell carcinoma Laryngoscope 83 1973 2012
133. L.A. Manson Does antibody-dependent epitope masking permit progressive turnour growth in the face of cell-mediated cytotoxicity? Immunol Today 12 1991 352
134. P. Marino M. Cugno A. Preatoni Increased levels of soluble interleukin-2 receptors in serum of patients with lung cancer Br J Cancer 61 1990 434
135. S.D. Marlin T.A. Springer Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1) Cell 51 1987 813
136. K.M. Matchett A.T. Huang W.B. Kremer Impaired lymphocyte transformation in Hodgkin's disease. Evidence for depletion of circulating T-lymphocytes J Clin Invest 52 1973 1908
137. M. Maxwell T. Galanopoulos J. Neville-Colden H. Antonaides Effect of the expression of transforming growth factor-B2 in primary human glioblastomas on immunosup-pression and loss of immune surveillance J Neurosurg 76 1992 799
138. S. Miescher T.L. Whiteside S. Carrel V. von Fliedner Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: Effects of tumor cells and their supernatants on proliferative responses of lymphocytes J Immunol 136 1986 1900
139. H. Mizoguchi J.J. O'Shea D.N. Longo Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice Science 258 1992 1795
140. B.P. Morgan Complement membrane attack on nucleated cells: Resistance, recovery and lethal effects Blochem J 263 1989 1
141. H. Nakagomi M. Petersson I. Magnusson Decreased expression of the signal-tranducing d chains in tumor-infiltrating T-cells and NK cells of patients with colo-rectal carcinoma Cancer Res 53 1993 5610
142. P. Natali M.R. Nicotra R. Cavaliere Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions Cancer Res 50 1990 1271
143. J.J. Neefjes F. Momburg G.J. Hammerling Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter Science 261 1993 769
144. R.S. Neiman P.J. Rosen R.J. Lukes Lymphocyte-depletion Hodgkin's disease. A clinico-pathological entity N Engl J Med 288 1973 751
145. T. Nemoto T. Han J. Monowada Cell-mediated immune status of breast cancer patients: An evaluation by skin tests, lymphocyte stimulation and counts of rosette-forming cells J Natl Cancer Inst 53 1974 641
146. R.J. North I. Bursuker Generation and decay of the immune response to a progressive fibrosarcoma J Exp Med 159 1984 1295
147. A.M. Nouri R.D. Hussain R.T. Oliver The frequency of major histocompatibility complex antigen abnormalities in urological rumours and their correction by gene trans-fection or cytokine stimulation Cancer Gene Therapy 1 1994 119
148. A.M. O'Mahony G.C. O'Sullivan J. O'Connell An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage J Immunol 151 1993 4847
149. H. Ohno T. Aoe S. Taki Developmental and functional impairment of T cells in mice lacking CD3d chains EMBO J 12 1993 4357
150. R.K. Oldham J.L. Weese R.B. Herberman Immunological monitoring and immuno-therapy in carcinoma of the lung Int J Cancer 18 1976 739
151. S. Ostrand-Rosenberg Tumor immunotherapy: The tumor cell as an antigen-pre-senting cell Curr Opin Immunol 6 1994 722
152. F. Pandolfi L. Trentin L.A. Boyle Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumor-infiltrating lymphocytes Cancer 69 1992 1165
153. W.R. Panje Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor Arch Otolaryngol 107 1981 658
154. P.R. Papenhausen A. Kukwa C.B. Croft Cellular immunity in patients with epidermoid cancer of the head and neck Laryngoscope 89 1979 538
155. L.C. Peltenburg P.I. Schreier Transcriptional suppression of HLA-B expression by c-Myc is mediated through the core promoter elements Immunogenetics 40 1994 54
156. 2) production by peripheral blood monocytes in Hodgkin's disease and malignant lymphoma J Clin Oncol 3 1985 641
157. L. Piali A. Fichtel H. Terpe Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma J Exp Med 181 1995 811
158. C.M. Pinsky H.F. Oettgen A. El Domeiri Delayed hypersensitivity reactions in patients with cancer Proc Am Assoc Cancer Res 12 1971 100
159. M.R. Posner E.L. Reinherz J. Breard Lymphold subpopulations of peripheral blood and spleen in untreated Hodgkin's disease Cancer 48 1981 1170
160. R.T. Prehn J.M. Main Immunity to methlycholanthrene-induced sarcomas J Nat Cancer Inst 18 1957 769
161. C.-H. Pui S.H. Ip P. Kung High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma Blood 70 1987 624
162. P.L. Reilly J.R. Waska D.D. Jeanfavre The native structure of intercellular adhesion molecule-1 (ICAM-1) is a dimer J Immunol 155 1995 529
163. A. Riesco Five-year cancer cure: Relation to total amount of peripheral lymphocytes and neutrophils Cancer 25 1970 135
164. A.B. Roberts M.B. Sporn R.K. Assoian Transforming growth factor type β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro Proc Natl Acad Sci USA 83 1986 4167
165. S. Romagnani P.L. Ferrini M. Ricci The immune derangements in Hodgkin's disease Semin Hematol 22 1985 41
166. S. Romagnani E. Maggi R. Biagiotti Altered proportions of Tµ- and Tγ-cell subpopulations in patients with Hodgkin's disease Scand J Immunol 7 1978 511
167. A.H. Rook J.H. Kehrl L.M. Wakefield Effects of transforming growth factor B on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness J Immunol 136 1986 3916
168. H.R. Rosen C. Ausch G. Reiner etak Downregulation of lymphocyte mitogenesis by breast cancer-associated p43 Cancer Lett 82 1994 105
169. T. Roszman L. Elliott W. Brooks Modulation of T-cell function by gliomas Immunol Today 12 1991 370
170. R. Rothlein M.L. Dustin S.D. Marlin T.A. Springer A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1 J Immunol 137 1986 1270
171. L.A. Rubin G. Jay D.L. Nelson The released interleukin-2 receptor binds interleukin-2 efficiently J Immunol 137 1986 3841
172. L.A. Rubin C. Kurman M.E. Fritz etak Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro J Immunol 135 1985 3172
173. T. Sakuma K. Kodama T. Hara etak Levels of complement regulatory molecules in lung cancer: Disappearance of the D17 epitope of CD55 in small-cell carcinoma Jpn J Cancer Res 84 1993 753
174. G.P. Schechter F. Soehnlen Monocyte-mediated inhibition of lymphocyte blastogenesis in Hodgkin's disease Blood 52 1978 261
175. W.W. Schier Cutaneous anergy and Hodgkin's disease N Engl J Med 250 1954 353
176. T. Seya T. Hara M. Matsumtot H. Akedo Quantitative analysis of membrane coafactor protein (MCP) of complement: High expression of MCP on human leukemia cell lines, which is downregulated during cell differentiation J Immunol 145 1990 238
177. W.L. Sibbett A.D. Bankhurst R.C. Williams Studies of cell subpopulations mediating mitogen hyporesponsiveness in patients with Hodgkin's disease J Clin Invest 61 1978 55
178. R.F. Silicano M.J. Solaski MHC class I-restricted processing of transmembrane proteins. Mechanism and biologic significance J Immunol 155 1995 2
179. J.E. Sokal N. Primikirios The delayed skin test response in Hodgkin's disease and lymphosarcoma Cancer 14 1961 597
180. N. Suciu-Foca J. Buda J. McManus etak Impaired responsiveness of lymphocytes and serum-inhibitory factors in patients with cancer Cancer Res 33 1973 2373
181. J.J. Sussman J.S. Bonifacino J. Lippincott-Schwartz etak Failure to synthesize the T cell CD3-d chain: Structure and function of a partial T cell receptor complex Cell 52 1988 85
182. H.T. Swan J. Knowelden Prognosis in Hodgkin's disease related to the lymphocyte count Br J Haematol 21 1971 343
183. K. Takahashi K. Ono Y. Hirabayashi M. Taniguchi Escape mechanisms of melanoma from immune system by soluble melanoma antigen J Immunol 140 1988 3244
184. A. Talento M. Nguyen S. Law etak Transfection of mouse cytotoxic T lymphocyte with an antisense granzyme A vector reduces lytic activity J Immunol 149 1992 4009
185. T. Terachi G. Stanescu J.E. Pontes etak Coexistence of autologous antibodies and decay-accelerating factor, an inhibitor of complement, on human renal tumor cells Cancer Res 51 1991 2521
186. D.G.T. Thomas C.B. Lannigan P.O. Behan Impaired cell-mediated immunity in human brain tumors Lancet 1 1975 1389
187. T. Toge S. Hamamoto E. Itagaki Concanavalin A-induced and spontaneous suppressor cell activities in peripheral blood lymphocytes and spleen cells from gastric cancer patients Cancer 52 1983 1624
188. S.E. Townsend J.P. Allison Tumor rejection after direct costimulation of CD8 + T cells by B7-transfected melanoma cells Nature 259 1993 368
189. M. Tsujisaki K. Imai H. Hirata etak Detection of circulating intercellular adhesion molecule-1 antigen in malignant diseases Clin Exp Immunol 85 1991 3
190. S. Tsunawaki M. Sporn A. Ding C. Nathan Deactivation of macrophages by transforming growth factor-B Nature 334 1988 260
191. J.J. Twomey L. Rice Impact of Hodgkin's disease upon the immune system Semin Oncol 7 1980 114
192. J.J. Twomey A.H. Laughter S. Farrow C.C. Douglass Hodgkin's disease. An immunode-pleting and immunosuppressive disorder J Clin Invest 56 1975 467
193. J.J. Twomey O. Sharkey J.A. Brown Cellular requirements for the mitotic response in allogenic mixed leukocyte cultures J Immunol 104 1970 845
194. P.L. Twomey W.J. Catalona P.B. Chretien Cellular immunity in cured cancer patients Cancer 33 1974 435
195. H. Udono P.K. Srivastava Comparison of tumor-specific immunogenetics of stress induced proteins gp96, hsp90 and hsp70 J Immunol 152 1994 5398
196. H. Udono P.K. Srivastava Heat shock protein 70-associated peptides elicit specific cancer immunity J Exp Med 178 1993 1391
197. J.L. Urban R.C. Burton J.M. Holland Mechanisms of syngeneic tumor rejection: Susceptibility of host-selected progressor variants to various immunological effector cells J Exp Med 155 1982 557
198. J.L. Urban M.L. Kripke H. Schreiber Stepwise immunological selection of antigenic variants during tumor growth J Immunol 137 1986 3036
199. J.L. Urban C. Van Waes H. Schreiber Pecking order among tumor-specific antigens Eur J Immunol 14 1984 181
200. C. Uyttenhove J. Maryanski T. Boon Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression J Exp Med 157 1983 1040
201. A. Vacca R. Di Stefano A. Frassanito A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myetoma Clin Exp Immunol 84 1991 429
202. A. Van Pel B. Van Der P. Coulie Genes coding for tumor antigens recognized by cytolytic T lymphocytes Immunot Rev 145 1995 229
203. G.A. Van Seventer Y. Shimizu K.J. Horgan S. Shaw The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells J Immunol 144 1990 4579
204. F. Vanky P. Wang M. Patarroyo E. Klein Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro Cancer Immunol Immunother 31 1990 19
205. R. Versteeg K.M. Kruse-Wolters A.C. Plomp Suppression of class I human histocompatibility leukocyte antigen by c-myc is locus specific J Exp Med 170 1989 621
206. P.F. Vinante G. Nadali M.M. Ricetti ICAM-1 tissue overexpression associated with increased serum levels of its soluble form in Hodgkin's disease Br J Haematol 84 1993 161
207. J. Von Roenn J.E. Harris D.P. Braun Suppressor cell function in solid tumor cancer patient J Clin Oncol 5 1987 150
208. B.M. Vose M. Moore Suppressor cell activity of lymphocytes infiltrating human lung and breast tumors Int J Cancer 24 1979 579
209. B.M. Vose P. Gallagher M. Moore P.F. Schofield Specific and nonspecific lymphocyte cytotoxicity in colon carcinoma Br J Cancer 44 1981 846
210. D.K. Wagner J. Kiwanuka B.K. Edwards Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: Correlation with survival J Clin Oncol 5 1987 1262
211. T. Waldman The structure, function, and expression of interleukin-2 receptors on normal and malignant lynphocytes Science 232 1986 727
212. R.A. Walker S.J. Dearing B. Gallacher Relationship of transforming growth factor β1 to extracellular matrix and stromal infiltrates in invasive breast cancer Br J Cancer 69 1994 1160
213. L.A. Walsh M. Tone H. Waldmann Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement Eur J Immunol 21 1991 847
214. H.J. Wanebo M.Y. Jun E.W. Strong H. Oettgen T-cell deficiency in patients with squamous cell cancer of the head and neck Am J Surg 130 1975 445
215. H.J. Wanebo B. Rao N. Miyazawa Immune reactivity in primary carcinoma of the lung and its relation to prognosis J Thorac Cardiovasc Surg 72 1976 339
216. H.J. Wanebo T. Riley D. Katz Indomethacin sensitive suppressor-cell activity in head and neck cancer patients Cancer 61 1988 462
217. Z. Wang Y. Cao A.P. Albino Loss of HLA class I antigen expression by melanomacells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA J Clin Invest 91 1993 684
218. S.A. Weitzman A.C. Aisenberg G.R. Siber D.H. Smith Impaired humoral immunity in treated Hodgkin's disease N Engl J Med 297 1977 245
219. T.L. Whiteside R.H. Goldfarb Antitumor effector cells: Extravasation and control of metastasis Immunology Series 61 1994 159
220. E.A. Wiedenfeld M. Fernandez-Vina J.A. Berzofsky D.P. Carbone Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif Cancer Res 54 1994 1175
221. S.F. Winter J.D. Minna B.E. Johnson Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation Cancer Res 52 1992 4168
222. S.F. Winter Y. Sekido J.D. Minna Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: Association with improved survival J Natl Cancer lnst 85 1993 2012
223. I.P. Witz S. Kinamon M. Ran G. Klein Tumor-bound immunoglobulins. The in vitro fixation of radioiodine-labeled antiimmunoglobulin reagents by tumor cells Clin Exp Immunol 16 1974 321
224. G.T. Wolf S. Schmaltz J. Hudson Alterations in T-lymphocyte subpopulations in patients with head and neck cancer Arch Otolaryngol Head Neck Surg 113 1987 1200
225. T.P.U. Wustrow W.J. Issing Immune defects in patients with head and neck cancer Anticancer Res 13 1993 2507
226. J. Yagtie J. White C. Coleclough The T cell receptor: The α and β chains define idiotype and antigen MHC specificity Cell 42 1985 81
227. R.C. Young M.P. Corder H.A. Haynes Delayed hypersensitivity in Hodgkin's disease Am J Med 52 1972 63
228. A. Yu H. Watts N. Jaffe R. Parkman Concomitant presence of tumor specific cytotoxic and inhibitor lymphocytes in patients with osteogenic sarcoma N Engl J Med 297 1977 121
229. M. Zembala B. Mytar T. Popiela G.L. Asherson Depressed in vitro peripheral blood lymphocyte response to mitogens in cancer patients: The role of suppressor cells Int J Cancer 19 1977 605
230. B. Zerler The soluble interleukin-2 receptor as a marker for human neoplasia and immtme status Cancer Cells 3 1991 471
231. J. Zhao S.A. Rollins S.E. Maher Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement J Biol Chem 266 1991 13418
232. R.M. Zinkernagel P.C. Doherty MHC-restricted cytotoxic T cell studies on the biological role of the polymorphic major transplantation antigens determining T-cell restric-tion-specificity, function, and responsiveness Adv Immunol 27 1979 51
233. P. Zuber M.C. Kuppner N. de Tribolet Transforming growth factor-B2 down-regulates HLA-DR antigen expression on human malignant glioma cells Eur J Immunol 18 1988 1623